“IL-17 Inhibition vs IL-23 Inhibition for Psoriatic Arthritis: An Ongoing Debate”, Can Rheumatol Today, vol. 2, no. 2, pp. 4–14, Aug. 2025, doi: 10.58931/crt.2025.2262.